Author · brief 2026-06-22

@7Innovator 7Innovator

grade Bcorporatex.com/7Innovator ↗

Disciplined disruptive-growth analyst who DCFs innovators and admits when they're overpriced

Publishes fundamental theses and valuation models (DCF, ROIC

trader score
+0.56
hit rate
55%
mean α
+0.53%
signals 14d
10

Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY. · Analyst brief as of 2026-06-22.

Their picks, scored

Across their last 20 scored bets: 55% hit rate, +0.53% mean alpha, trader score +0.56. Their last-14d mentions, direction-adjusted, have moved -5.4% since posting (mean over 10 mentions with price data).

AI compute challengers, hot IPOs, and Lab-stock momentum

7Innovator is focused on AI compute architecture shifts, especially alternatives to Nvidia GPU dominance and Cerebras as a post-IPO challenger. The distinctive read is less a direct single-name trade and more a framework: Moore's Law slowing creates room for new chip architectures, expensive AI IPOs, and selective high-growth ideas. Later in the window, attention shifts to a lighter bullish basket around Lab-name stocks with chart context.

Themes3analyst read · 2026-06-22
AI compute architecture beyond Moore's Law
mixedNEW5 signals
⚠ 60% of theme signals are NVDA — flag pump risk
Cerebras IPO challenge to Nvidia
mixedintensifying7 signals
⚠ 43% of theme signals are NVDA — flag pump risk
Lab-name chart momentum basket
bullNEW4 signals
Direction this week

The week is concentrated in AI compute disruption, with repeated attention on NVDA alternatives and CBRS as a high-growth but valuation-sensitive AI IPO. There are no CALL_DIRECTIONAL or POSITION_DISCLOSURE signals, so no explicit adds, trims, exits, or position flips can be inferred. Late-window activity broadens into a bullish Lab-name chart basket across ALAB, PL, and RKLB rather than a disclosed trade.

Best hypotheses5their highest-scoring claims in our index
Agentic AI should expand enterprise software demand rather than destroy CRM’s core software opportunity.
bullHIGH6 co-supporters
ABBV is being framed as a quality dividend healthcare holding, helped by analyst upgrades, yield appeal, and disclosed l
bullHIGH10 co-supporters
RKLB valuation is stretched after the rally, making the stock hard to justify without fresh major catalysts.
bearHIGH5 co-supporters
CRM remains undervalued versus cash flow, earnings, buybacks, and balance-sheet quality.
bullHIGH5 co-supporters
ZS offers a stronger relative cybersecurity setup than peers because growth and valuation look more favorable than CRWD
bullMEDIUM2 co-supporters
Recent signals10receipts included
date (PT)tickerauthorsentwhat they saidsince thenreceipt
2026-06-29QNT@7Innovator+0.15Promotes watch list research on Arqit and Quantinuum plus recommendations.+2.4%
2026-06-29ARQQ@7Innovator+0.15Promotes watch list research on Arqit and Quantinuum plus recommendations.-13.9%
2026-06-29ARQQ@7Innovator+0.35Adds ARQQ to watch list with balanced quantum encryption bull case and high-risk caveats.-13.9%
2026-06-26CME@7Innovator+0.55Bullish thesis on CME: record revenues, 70% operating margin and attractive decade valuation.+7.1%
2026-06-24CME@7Innovator+0.50Calls CME an undervalued dividend gem.+2.1%
2026-06-24CME@7Innovator+0.40Promotes CME as a dividend-paying gem in livestream.+2.1%
2026-06-24CME@7Innovator+0.65Says CME looks like an undervalued buying opportunity with strong margins and dividend.+2.1%
2026-06-23INFQ@7Innovator+0.30Recommends quantum computing discussion including listed innovators.-22.9%
2026-06-23QNT@7Innovator+0.30Recommends quantum computing discussion including listed innovators.-3.7%
2026-06-23IONQ@7Innovator+0.30Recommends quantum computing discussion including listed innovators.-15.1%

Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.